Biology pharmacy is in 2020 especially fervent, should market demand and capital upsurge, each old drug look forward to enlarges cop of research and development ceaselessly. The bag outside development of contract of drug of substance of opposite of this one trend and production (CRO) the development of the industry, it is an enormous stimulus.
This year the beginning of the year, the DP7 of factory of preparation of a biology that bright biology bought medicine to do obeisance to ear to be located in Germany to strap Wokusen, according to the agreement, this factory will by medicine bright biology is in charge of operation, jump as division of product of the company that do obeisance to ear strange? (Kovaltry, recombine defy hemophiliac factor) auxiliary production serves trader.
Now, bright biology is in medicine Germany is farther outspread, with getting used to the market demand that expands ceaselessly.
On December 21, 2020, bright biology and Germany do obeisance to medicine ear announces to reach to be bought newly trade. Bright biology will buy drug the factory of biology medicine former fluid that does obeisance to ear to be located in Er of tower of German five Po, supply a network with seeking those who strengthen new coronal vaccine and preparation of other live thing. Bilateral plan signs long-term relet agreement and transfer service contract, trade total amount is 150 million euro about. Trade this to still need superintendency department approval, predict to will be finished first half of the year 2021.
The plant of biology medicine former fluid that buys this (medicine bright biology former fluid 19 factories, MFG19) the area amounts to 30 thousand square metre, include 3 1000 litres of fill shedding mix 6 2000 litres shed the establishment of downstream form a complete set that adds product line and independence, farther promotion drug the whole world of medicine of biology of vaccinal to new coronal etc supplies bright biology ability. MFG19 will be mixed the biology preparation factory that is located in Germany to strap Wokusen (DP7) reach combination, bright biology supplies the drug that help strength commercialize production to serve. MFG19 and DP7 predict to will throw production inside 2021, for medicine production of bright biology Europe supplies catenary to provide strong support.
Once this still waits for what superintendency branch approves to trade,obtain approve and knock calm, will promote drug greatly bright biologic is produced can. Predict 2023, bright biology is in medicine to always be produced of the United States, China, Ireland, Germany and Singapore factory can will exceed 280 thousand litres, produce can enlarge general ensures bright biology passes drug further the ability that perfects the whole world to supply catenary network to supply biology drug for the client.
Medicine presiding apparitor Dr. Chen Zhisheng represents bright live thing: "Regard the key that Europe supplies catenary network as one annulus, MFG19 will with medicine bright biology is had produce can produce powerful synergism, strong consolidate ' global twin plant is produced ' the strategy. We will provide high quality and efficient manufacturing service continuously, endow with can global partner, benefit wide a serious illness suffers from. Benefit wide a serious illness suffers from..
Medicine bright biology is ability of pharmacy of biology of an open mode, unifinication and technical ode can platform, offer all-around end to serve to upright research and development for company of global biology pharmacy and biology technology company, help drug of organisms of discovery of medical look forward to, development and production. Up to on June 30, 2020, in medicine the integrated project of the research and development on bright biology platform amounts to 286, include 141 to be in clinical before research phase, 125 are in clinical and inchoate (I period, II period) level, 19 are in later period is clinical (III period) and be in 1 times commercialize stage of production.
Medicine bright biologic predecessor is medical Ming Kangde's new biology pharmacy and biology craft ministry, its expand quickly produce can pace wants restrospect to 2015. Upsurge of research and development of drug of biology of benefit from benefit from, bright biology removed the drug that gives priority to course of study with CRO 2015 oneself, battalion closes to maintain high speed growth from beginning to end.
2015, medical Ming Kangde announces to undertake be changinged demesne in the US stock. After two years, bright biology regards medicine as medicine Ming Kangde is changed demesne " tear open 3 " harbor of a leave for different destinations appear on the market, collect 3.782 billion HK dollar, for next in a large-scale dilate is produced can lay next corporeal foundations.
2018, bright biology shows drug outstanding achievement, its do business income grows 56.6% to reach 2.535 billion yuan compared to the same period, completely profit criterion increase sharply 149.6% reach 631 million yuan. Be in merely 2018 first half of the year, medicine bright biology announced with respect to in succession 3 investment build a decision, predict in Shijiazhuang, Singapore and Ireland 3 ground build manufacturing base respectively. Announcement announces information to show, american base will invest 470 million HK dollar, singapore base will invest 467 million HK dollar, irish base will invest 3.1 billion HK dollar, shijiazhuang base 1.88 billion HK dollar, total investment will exceed 6 billion HK dollar. In March 2019, bright biology announced medicine again the company was expanding 2019 produce the investment that can go up: 4 billion yuan.
2020, suffer epidemic situation effect, bright biology receives medicine to fight virus of new-style coronal shape to counteract sheet of antibody project ask in great quantities during epidemic situation, signed even more inside 3 months 10 projects; On the other hand, bright biology enlarge produces drug can, the pace that builds the whole world to supply chain still also is in continuously, this year first half of the year, bright biology is in medicine the United States established two biology drug clinical and commercialize manufacturing base, finish buy plant of German biology preparation, the biology pharmacy that is located in Ireland produces the main body building of base to be finished basically also.
What wait for immune therapeutics as PD-1/PD-L1, Car-T is arisen reach analogue of first live thing of domestic to obtain batch appear on the market, the demand of biology pharmacy domain expands ceaselessly, bright biology enlarges medicine produce can pace and " global twin plant is produced " the strategy still is met probably go down continuously.
